FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous ... at home using an autoinjector. The injection process is expected to take, on average, 15 seconds.
Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...
Biogen does not undertake any obligation to publicly update any forward-looking statements. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc ...
The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...
The brokerage also questioned the commercial potential of Biogen’s Alzheimer’s drug Leqembi, despite advancements like a subcutaneous auto-injector and ongoing studies. “We remain cautious ...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...
Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback